Pregled bibliografske jedinice broj: 559654
Dose adjusted EPOCH – Rituximab as first line treatment for high risk, aggressive B-NHL : a single center experience
Dose adjusted EPOCH – Rituximab as first line treatment for high risk, aggressive B-NHL : a single center experience // Abstracts of the Leukemia and Lymphoma Meeting "East and west are together"
Dubrovnik, Hrvatska, 2011. (poster, nije recenziran, sažetak, znanstveni)
CROSBI ID: 559654 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Dose adjusted EPOCH – Rituximab as first line treatment for high risk, aggressive B-NHL : a single center experience
Autori
Pejša, Vlatko ; Prka, Željko ; Lucijanić, Marko ; Jakšić, Ozren ; Piršić, Mario ; Ajduković, Radmila ; Kušec, Rajko
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Abstracts of the Leukemia and Lymphoma Meeting "East and west are together"
/ - , 2011
Skup
Leukemia and Lymphoma Meeting "East and west are together"
Mjesto i datum
Dubrovnik, Hrvatska, 17.09.2011. - 21.09.2011
Vrsta sudjelovanja
Poster
Vrsta recenzije
Nije recenziran
Ključne riječi
NHL; DA-EPOCH; high risk
Sažetak
In this report we presented 22 patients with high risk diffuse large B-cell lymphoma. Our results showed that DA-EPOCH-R is highly effective regimen in this group of patients. These results are conclusive with results of Garcia-Suarez and colleagues (Garcia-Suarez J et al. British journal of Haematology 2007 ; 136:276-285) who also find this regimen effective as first line treatment in DLBCL patients. Some of our patients were consolidated with autoHSCT due to high proliferation index or IPI≥3. Only 1 patient relapsed during follow up period. Of 6 patients who were transplated, all but one are still in CR. We conclude that DA-EPOCH-R is highly effective regimen as first line treatment in high risk diffuse large B-cell lymphoma.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Napomena
Rad je kao predavanje prezentiran i na skupu 16th Congress of EHA, održanom od 09-12.06.2011., London, Velika Britanija.
POVEZANOST RADA
Projekti:
108-1980955-3094 - Genetika i funkcija hematopoeze i mikrookoliša Ph- mijeloproliferativnih bolesti (Kušec, Rajko, MZOS ) ( CroRIS)
198-1980955-0953 - Imunobiologija kronične B-limfocitne leukemije i mikrookoliš (Jakšić, Ozren, MZOS ) ( CroRIS)
198-1980955-0954 - Novi klinički pristupi kroničnim mijelo i limfoproliferacijama (Pejša, Vlatko, MZOS ) ( CroRIS)
Ustanove:
Klinička bolnica "Dubrava"
Profili:
Rajko Kušec
(autor)
Željko Prka
(autor)
Ozren Jakšić
(autor)
Marko Lucijanic
(autor)
Vlatko Pejša
(autor)